Bicycle Therapeutics (NASDAQ:BCYC) Releases Earnings Results, Beats Estimates By $0.05 EPS

Bicycle Therapeutics (NASDAQ:BCYC) released its quarterly earnings data on Thursday. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.58) by $0.05, Fidelity Earnings reports. The business had revenue of $0.61 million for the quarter, compared to the consensus estimate of $1.00 million.

BCYC traded down $0.04 during trading on Friday, hitting $8.45. The stock had a trading volume of 8,000 shares, compared to its average volume of 32,629. Bicycle Therapeutics has a twelve month low of $6.24 and a twelve month high of $14.91. The business’s 50 day simple moving average is $9.98.

A number of research firms have recently issued reports on BCYC. Canaccord Genuity set a $22.00 price objective on shares of Bicycle Therapeutics and gave the company a “buy” rating in a research note on Monday, September 30th. Goldman Sachs Group upgraded shares of Bicycle Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, September 11th. Finally, Zacks Investment Research downgraded shares of Bicycle Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 7th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $19.50.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics Limited, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease.

Recommended Story: How to Invest in Marijuana Stocks

Receive News & Ratings for Bicycle Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bicycle Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply